Flotations tank in the first quarter
A correction – as long as it is not too severe – might not be a bad thing for the sector.
After a record year, where next for biopharma flotations?
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
